Zhang Xiaozhu, Zhao Yi, Wang Miao, Yap Wee See, Chang Alex Yuang-chi
Johns Hopkins Singapore International Medical Centre, Singapore 308433, Singapore.
Lung Cancer. 2008 May;60(2):175-82. doi: 10.1016/j.lungcan.2007.10.011. Epub 2007 Dec 3.
Cells or cell-free fluid of malignant pleural effusion could be important clinical specimen for epidermal growth factor receptor (EGFR) mutation screening in advanced non-small cell lung cancer (NSCLC) patients. However, their usefulness in mutation detection has not been well compared. In this study we recruited 26 East Asian NSCLC patients with malignant pleural effusion, determined the mutation status of EGFR in both cells and matched cell-free fluid with the use of sequencing and mutant-enriched PCR. After comparing the mutation spectrums, we found both the cells and cell-free pleural fluid may be feasible clinical specimen for EGFR mutation detection in unresectable NSCLC given sensitive genotyping assays employed. Direct sequencing could miss a significant portion of mutations in these heterogeneous specimens. More sensitive methods, such as mutant-enriched PCR and gene scan, could provide more reliable mutational information.
恶性胸腔积液的细胞或无细胞液体可能是晚期非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变筛查的重要临床标本。然而,它们在突变检测中的效用尚未得到充分比较。在本研究中,我们招募了26例患有恶性胸腔积液的东亚NSCLC患者,使用测序和突变富集PCR确定了细胞和配对的无细胞液体中EGFR的突变状态。在比较突变谱后,我们发现,鉴于采用了灵敏的基因分型检测方法,细胞和无细胞胸腔积液都可能是不可切除NSCLC中EGFR突变检测的可行临床标本。直接测序可能会遗漏这些异质标本中相当一部分突变。更灵敏的方法,如突变富集PCR和基因扫描,可提供更可靠的突变信息。